Fruytier Lawyers in Business advises Kreos Capital on its €15 million growth capital investment
Fruytier Lawyers in Business advised Kreos Capital V (UK) on its €15 million growth capital investment in Kiadis Pharma N.V. (“Kiadis Pharma”), a Dutch company listed on Euronext Amsterdam and Euronext Brussels.
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders. Its product candidates have the potential to make allogeneic hematopoietic stem cell transplantations (HSCT) safer and more effective for patients.
Kiadis Pharma announced to the market that it will use the financing to advance the development of its ATIR products, for general corporate purposes and to repay €5.3 million of existing Dutch Government Loans.
Fruytier Lawyers in Business’ core team comprised Vincent van Oosteren and Myrddin van Westendorp from our Corporate Team. Charles Russell Speechlys LL advised on matters of UK law and Borden Ladner Gervais LLP on matters of Canadian law respectively.
See also this article of Market Insiders: http://markets.businessinsider.com/news/stocks/kiadis-pharma-obtains-up-to-15-million-debt-financing-from-kreos-capital-1002265039